Literature DB >> 33826109

Comment on 'Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials'.

Marco Tullio Suadoni1.   

Abstract

Entities:  

Year:  2021        PMID： 33826109     DOI： 10.1007/s40261-021-01029-2

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  3 in total

1.  Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.

Authors:  Akshaya Srikanth Bhagavathula; Nadya Obaid Al Matrooshi; Cain C T Clark; Jamal Rahmani
Journal:  Clin Drug Investig       Date:  2020-12-23       Impact factor: 2.859

2.  Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

Authors:  Paul D Thompson; Diane E MacDougall; Roger S Newton; Janice R Margulies; Jeffrey C Hanselman; David G Orloff; James M McKenney; Christie M Ballantyne
Journal:  J Clin Lipidol       Date:  2016-01-06       Impact factor: 4.766

3.  Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Authors:  Christie M Ballantyne; Ulrich Laufs; Kausik K Ray; Lawrence A Leiter; Harold E Bays; Anne C Goldberg; Erik Sg Stroes; Diane MacDougall; Xin Zhao; Alberico L Catapano
Journal:  Eur J Prev Cardiol       Date:  2019-07-29       Impact factor: 7.804
  3 in total
  1 in total

1.  Authors' Reply to 'Comment on: Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials'.

Authors:  Akshaya Srikanth Bhagavathula; Nadya Obaid Al Matrooshi; Cain C T Clark; Jamal Rahmani
Journal:  Clin Drug Investig       Date:  2021-04-11       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.